Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRANUS phase II study of atezolizumab plus tiragolumab with chemoradiotherapy in localized anal squamous cell carcinoma
2021-005887-24Phase 2Active
- Sponsor
- GEMCAD
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in anal squamous cell carcinoma (SCCA) and anal carcinoma, sponsored by GEMCAD. Primary endpoint: Clinical complete response rate at week 26. Started Nov 2022; status: active.
02
Drugs
tiragolumabatezolizumab
03
Conditions
anal squamous cell carcinoma (SCCA)anal carcinoma
Beyond the preview
Go deeper on 2021-005887-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005887-24.